Alcohol Use Disorder (Alcohol Dependence)

1. Clinical Overview

Summary

Alcohol Use Disorder (AUD), previously termed alcohol dependence, is a chronic, relapsing neurobiological condition characterised by compulsive alcohol seeking and use despite harmful consequences, impaired control over consumption, tolerance, and physical withdrawal symptoms. The DSM-5 conceptualises AUD on a severity continuum (mild, moderate, severe) based on the number of diagnostic criteria met. AUD represents a major global public health burden, contributing significantly to liver disease, cardiovascular disease, neurological damage, cancers, accidents, violence, and psychiatric comorbidity.

The condition affects approximately 5.1% of the global disease burden and causes 3 million deaths annually worldwide. In the UK, approximately 1.6 million people meet criteria for alcohol dependence, with only a minority accessing treatment. Early identification using validated screening tools (AUDIT, CAGE, FAST) combined with evidence-based treatment integrating pharmacotherapy, psychosocial interventions, and mutual aid groups can substantially improve outcomes. The prevention and treatment of Wernicke's encephalopathy through timely thiamine supplementation remains critical — this is a medical emergency with potentially irreversible consequences if missed.

Key Facts

Clinical Pearls

"Always Thiamine BEFORE Glucose": In any patient with suspected alcohol problems and altered consciousness, nutritional deficiency, or receiving IV fluids, give IV Pabrinex (thiamine) BEFORE giving IV glucose. Glucose metabolism consumes thiamine and can precipitate or worsen Wernicke's encephalopathy. This is a crucial exam point and clinical priority.

CAGE Screening Mnemonic: Have you ever felt you should Cut down? Have people Annoyed you by criticising your drinking? Have you felt Guilty about drinking? Have you ever had a morning Eye-opener (drink first thing)? Score ≥2 positive responses suggests problematic drinking requiring further assessment.

Wernicke's Triad Recognition: Confusion, Ataxia, Ophthalmoplegia — but the full classic triad is present in only 10-16% of cases. Have a very low threshold to treat suspected cases empirically. Any patient with alcohol misuse and any neurological symptom should receive thiamine.

The "Alcohol Paradox": Higher socioeconomic groups drink more frequently, but lower socioeconomic groups experience more alcohol-related harm. This inverse relationship between consumption patterns and harm burden is important for public health planning.

CIWA-Ar Scoring: Clinical Institute Withdrawal Assessment for Alcohol (revised) guides benzodiazepine dosing in withdrawal. Score less than 10 = mild (may not need pharmacotherapy); 10-18 = moderate; > 18 = severe (high-dose benzodiazepine required). Symptom-triggered dosing reduces medication exposure and length of treatment.

Why This Matters Clinically

Alcohol use disorder is extremely common and frequently undetected in clinical practice. It affects virtually every organ system and represents a leading cause of preventable morbidity and mortality. Many patients present with physical consequences (liver disease, trauma, pancreatitis, cardiac arrhythmias) without disclosing their drinking patterns, and clinicians must maintain a high index of suspicion. Withdrawal can be life-threatening if not managed properly, yet is eminently treatable with appropriate pharmacological support. Recovery is absolutely achievable with appropriate intervention — many patients attain long-term sustained remission with quality of life comparable to the general population.

---

2. Epidemiology

Incidence & Prevalence

The global burden is substantial. The WHO Global Status Report on Alcohol and Health (2018) documented that alcohol consumption contributes to more than 200 disease and injury conditions and is causally linked to major non-communicable diseases including liver cirrhosis, cardiovascular disease, and multiple cancers.

Demographics

Risk Factors

Non-Modifiable Risk Factors:

• Genetic factors: Heritability approximately 50%; polymorphisms in ADH1B, ALDH2, GABRA2, OPRM1 genes influence risk
• Family history: First-degree relative with AUD increases risk 4-7 fold
• Male sex: Higher prevalence (though women have accelerated progression)
• Early age of first drink: Onset less than 15 years increases lifetime AUD risk significantly
• Psychiatric comorbidity: Depression, anxiety disorders, PTSD, ADHD, bipolar disorder
• Personality traits: Impulsivity, sensation-seeking, neuroticism
• Adverse childhood experiences: Trauma, abuse, neglect

Modifiable Risk Factors:

Burden of Disease

---

3. Pathophysiology

Neurobiological Mechanism

Alcohol produces its effects through complex interactions with multiple neurotransmitter systems, leading to neuroadaptive changes that underpin tolerance, dependence, and withdrawal.

Stage 1: Acute Alcohol Effects (Intoxication)

Stage 2: Neuroadaptation (Chronic Use → Tolerance)

With repeated exposure, the brain adapts to maintain homeostasis:

Stage 3: Withdrawal State (CNS Hyperexcitability)

When alcohol is removed, the adapted brain enters a hyperexcitable state:

Stage 4: Addiction Cycle (Compulsive Use)

Multi-Organ System Damage

Chronic alcohol use causes widespread organ pathology through multiple mechanisms including direct toxicity, metabolic effects, nutritional deficiencies, and immune dysregulation.

Wernicke-Korsakoff Syndrome: Critical Pathophysiology

This thiamine (vitamin B1) deficiency syndrome is a medical emergency and exam favourite.

Mechanism: Thiamine pyrophosphate is essential cofactor for:

• Pyruvate dehydrogenase (glycolysis → citric acid cycle)
• α-ketoglutarate dehydrogenase (citric acid cycle)
• Transketolase (pentose phosphate pathway)

Deficiency → impaired ATP production in metabolically active brain regions → neuronal death.

Why alcohol causes thiamine deficiency:

1. Poor dietary intake
2. Impaired GI absorption
3. Reduced hepatic storage
4. Reduced phosphorylation to active form
5. Increased utilisation

---

4. Clinical Presentation

DSM-5 Diagnostic Criteria for Alcohol Use Disorder

A problematic pattern of alcohol use leading to clinically significant impairment or distress, manifested by ≥2 of the following within a 12-month period:

Severity Specifiers:

• Mild: 2-3 criteria
• Moderate: 4-5 criteria
• Severe: 6 or more criteria

ICD-11 Criteria (for comparison)

ICD-11 distinguishes between:

• Hazardous alcohol use (pattern increasing risk of harm)
• Harmful alcohol use (pattern causing health damage)
• Alcohol dependence (impaired control, physiological features, continued use despite harm)

Alcohol Withdrawal Syndrome: Timeline and Features

Early Withdrawal Symptoms (6-24 hours):

• Tremor — Classic early sign, often coarse, postural
• Sweating — Diaphoresis, often profuse
• Tachycardia — Heart rate > 100 bpm
• Hypertension — Elevated blood pressure
• Anxiety/agitation — Restlessness, irritability
• Nausea and vomiting — GI upset
• Insomnia — Difficulty sleeping
• Headache — Common complaint

Delirium Tremens (48-96 hours, Severe):

[!CAUTION] Delirium Tremens is a medical emergency with 5-15% mortality if untreated.

• Severe confusion/delirium with fluctuating level of consciousness
• Vivid visual hallucinations (classically small animals, insects — "formication")
• Profound autonomic instability (fever, severe tachycardia, hypertension, sweating)
• Marked agitation, tremulousness
• Risk factors: Prior DTs, concurrent illness, older age, severe dependence, high recent intake

Physical Examination Findings

Signs of Acute Intoxication:

• Smell of alcohol on breath
• Slurred speech
• Unsteady gait/ataxia
• Nystagmus
• Conjunctival injection
• Reduced consciousness

Signs of Chronic Alcohol Use:

Red Flags Requiring Urgent Action

[!CAUTION] Red Flags — Immediate Action Required:

Red Flag	Action	Rationale
Wernicke's encephalopathy (any of: confusion, ataxia, eye signs, hypothermia)	Pabrinex IV 2 pairs TDS immediately (BEFORE glucose)	Medical emergency; irreversible if untreated
Delirium tremens (confusion + hallucinations + autonomic instability)	HDU/ICU; high-dose benzodiazepines; IV fluids; thiamine	5-15% mortality untreated
Withdrawal seizures	Benzodiazepine; exclude other causes; prevent aspiration	Risk of status epilepticus
GI bleeding (haematemesis, melaena)	Resuscitation; urgent endoscopy; variceal protocol if suspected	Variceal bleeding has high mortality
Hypoglycaemia	Check glucose; treat with IV dextrose (AFTER thiamine)	Impaired gluconeogenesis
Suicidal ideation	Psychiatric assessment; safety planning; supervision	High comorbidity; high risk
Signs of liver failure (encephalopathy, coagulopathy, jaundice)	Urgent gastroenterology/hepatology input	Decompensated cirrhosis
Aspiration pneumonia	Airway protection; antibiotics	Common complication

---

5. Clinical Examination

Structured Approach

General Inspection:

• Nutritional status (often poor, cachectic)
• Signs of intoxication vs withdrawal
• Stigmata of chronic liver disease
• Signs of self-neglect
• Trauma/bruising
• Tremor (hands, tongue)

OSCE-Style Examination Sequence:

1. Hands and Arms

   • Tremor (ask patient to hold hands outstretched)
   • Dupuytren's contracture (palmar fascia thickening)
   • Palmar erythema (thenar and hypothenar)
   • Leuconychia (white nails — hypoalbuminaemia)
   • Clubbing (if cirrhosis)
   • Bruising (coagulopathy)
   • Muscle wasting
   • Asterixis/flapping tremor (hepatic encephalopathy)

2. Face and Eyes

   • Jaundice (scleral icterus)
   • Parotid enlargement (bilateral)
   • Telangiectasia
   • Nystagmus
   • Ophthalmoplegia (6th nerve palsy most common in Wernicke's)
   • Conjunctival pallor (anaemia)

3. Chest

   • Spider naevi (count — > 5 significant)
   • Gynaecomastia
   • Loss of axillary hair

4. Abdomen

   • Distension (ascites)
   • Caput medusae
   • Hepatomegaly OR small liver
   • Splenomegaly
   • Shifting dullness and fluid thrill

5. Neurological

   • Peripheral neuropathy (glove-and-stocking pattern)
   • Cerebellar examination (ataxia, dysarthria, nystagmus, intention tremor)
   • Cognitive screening (confusion, orientation, memory)
   • Gait assessment

6. Mental State

   • Orientation
   • Mood (depression common)
   • Suicidal ideation
   • Insight
   • Motivation for change

Screening Tools

AUDIT Questions (for reference):

1. How often do you have a drink containing alcohol?
2. How many units do you drink on a typical drinking day?
3. How often do you have 6+ units on a single occasion?
4. How often have you found you were unable to stop drinking once started?
5. How often have you failed to do what was expected because of drinking?
6. How often have you needed a first drink in the morning?
7. How often have you had guilt or remorse after drinking?
8. How often have you been unable to remember the night before?
9. Have you or someone else been injured due to your drinking?
10. Has a relative, friend, or health worker suggested you cut down?

---

6. Investigations

Bedside Tests

Laboratory Investigations

Imaging

Diagnostic Criteria Summary

DSM-5 Alcohol Use Disorder Diagnosis:

• ≥2 of 11 criteria within 12-month period
• Mild: 2-3 criteria
• Moderate: 4-5 criteria
• Severe: 6+ criteria

ICD-11 Alcohol Dependence:

• Impaired control over alcohol use
• Increasing priority of alcohol over other activities
• Physiological features (tolerance and/or withdrawal)
• Persistent use despite harm

---

7. Management

Management Overview

Management of AUD involves four key phases:

1. Assessment and stabilisation (including emergency management)
2. Medically-assisted withdrawal (detoxification)
3. Relapse prevention (pharmacological and psychosocial)
4. Long-term recovery support

Community vs Inpatient Withdrawal: Decision Framework

Medically-Assisted Withdrawal (Detoxification)

Benzodiazepine Regimens:

Example Fixed-Dose Chlordiazepoxide Regimen (Moderate Dependence, SADQ 15-30):

Symptom-Triggered Dosing (Using CIWA-Ar):

• Assess CIWA-Ar score hourly initially
• CIWA-Ar less than 10: No medication required; reassess in 4-8 hours
• CIWA-Ar 10-18: Give chlordiazepoxide 10-20 mg; reassess in 1 hour
• CIWA-Ar > 18: Give chlordiazepoxide 20-40 mg; reassess in 1 hour
• Continue until CIWA-Ar less than 10 for 24-48 hours

Advantages of symptom-triggered: Less total medication, shorter treatment duration, reduced sedation.

Carbamazepine:

• Alternative if benzodiazepines contraindicated
• 200 mg TDS reducing over 7 days
• Does not prevent seizures as effectively as benzodiazepines

Thiamine and Vitamin Supplementation: Critical

CRITICAL PRINCIPLES:

1. Thiamine BEFORE glucose — always
2. IV/IM before oral — GI absorption impaired in alcohol-dependent patients
3. High dose for high risk — Pabrinex contains 250 mg thiamine per pair
4. Treat empirically — do not wait for confirmation in suspected Wernicke's
5. Duration matters — continue until no further improvement, minimum 5 days IV for Wernicke's

Other Nutritional Supplementation:

• Magnesium (often depleted; contributes to seizure risk)
• Phosphate (monitor for refeeding syndrome)
• Potassium (frequently low)
• Folate
• B-complex vitamins

Relapse Prevention Pharmacotherapy

NICE Recommendations:

• Offer acamprosate OR oral naltrexone as first-line relapse prevention
• Consider disulfiram for those who prefer a deterrent approach (with supervision)
• Consider nalmefene for reducing consumption in those not seeking immediate abstinence

Psychosocial Interventions

FRAMES Model for Brief Intervention:

• Feedback: Provide personalised feedback on risk/harm
• Responsibility: Emphasise personal responsibility for change
• Advice: Give clear advice to reduce/stop drinking
• Menu: Offer a menu of options/strategies
• Empathy: Use empathic listening style
• Self-efficacy: Support belief in ability to change

Referral Criteria

Refer to Specialist Addiction Services:

• Moderate-severe AUD (AUDIT ≥20, SADQ ≥15)
• Failed brief intervention in primary care
• Need for assisted withdrawal
• Complex needs (psychiatric comorbidity, poly-substance use)
• Pregnancy
• Young people (less than 18 years)

Refer to Inpatient/Residential Treatment:

• Severe dependence (SADQ ≥31)
• Failed community detox
• Unstable housing/homelessness
• Severe psychiatric comorbidity
• Complex medical needs
• History of complicated withdrawal

Urgent/Emergency Referral:

• Suspected Wernicke's encephalopathy
• Delirium tremens
• Withdrawal seizures
• Severe withdrawal (CIWA-Ar > 18)
• Suicidal ideation with plan/intent
• GI bleeding/acute liver failure

Disposition and Follow-up

---

8. Complications

Immediate Complications (Hours to Days)

Short-Term Complications (Weeks to Months)

Long-Term Complications (Months to Years)

Alcohol-Related Liver Disease Staging

---

9. Prognosis & Outcomes

Natural History

Without intervention, alcohol use disorder typically follows a progressive course with escalating consumption, increasing tolerance, emergence of withdrawal symptoms, development of physical and psychiatric complications, and social decline. However, the condition is highly treatable, and many people achieve sustained long-term recovery with appropriate intervention.

Treatment Outcomes

Prognostic Factors

Factors Associated with Better Prognosis:

• Strong social support network
• Stable housing and employment
• High motivation and engagement with treatment
• Active participation in mutual aid (AA, SMART Recovery)
• Medication adherence (acamprosate, naltrexone)
• Stable psychiatric health
• No prior complicated withdrawals
• Shorter duration of heavy drinking
• Younger age at treatment entry
• Female sex (better treatment response, though faster progression)
• Higher education level
• Married/partnered status

Factors Associated with Poorer Prognosis:

• Homeless or unstable housing
• Unemployment
• Poly-substance use
• Severe or untreated psychiatric comorbidity
• Multiple failed treatment attempts
• Lack of social support
• Continued contact with drinking network
• Severe dependence (SADQ ≥31)
• Long duration of heavy drinking
• Established cirrhosis
• Cognitive impairment
• Trauma/adverse childhood experiences (without treatment)
• Legal problems

Recovery Trajectories

Research demonstrates several common patterns:

1. Stable remission (~35-50%): Achieve abstinence and maintain it
2. Improved, non-abstinent (~20-30%): Significantly reduce consumption to low-risk levels
3. Relapsing-remitting (~20-30%): Periods of abstinence interspersed with relapse
4. Chronic refractory (~10-20%): Persistent heavy drinking despite treatment

Importantly, each treatment episode provides benefit, and many individuals require multiple attempts before achieving sustained recovery.

---

10. Evidence & Guidelines

Key Clinical Guidelines

Landmark Clinical Trials

COMBINE Study (2006) — Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence

Project MATCH (1997) — Matching Alcoholism Treatments to Client Heterogeneity

UKATT (2005) — UK Alcohol Treatment Trial

Cochrane Reviews and Meta-Analyses

Acamprosate for Alcohol Dependence (Cochrane 2010)

• 24 RCTs, 6,915 patients
• NNT = 9 for continuous abstinence at 6 months
• Significantly reduces risk of any drinking and increases cumulative abstinence duration
• Citation: Rösner S, et al. Cochrane Database Syst Rev. 2010;(9):CD004332. PMID: 20824837. DOI: 10.1002/14651858.CD004332.pub2

Naltrexone for Alcohol Dependence (Cochrane 2010)

• 50 RCTs
• Reduces heavy drinking (NNT = 9); smaller effect on abstinence
• Effect size: relative risk of heavy drinking 0.83
• Citation: Rösner S, et al. Cochrane Database Syst Rev. 2010;(12):CD001867. PMID: 21154349. DOI: 10.1002/14651858.CD001867.pub2

Benzodiazepines for Alcohol Withdrawal (Cochrane 2010)

• Strong evidence for preventing seizures and delirium tremens
• No significant differences between different benzodiazepines
• Symptom-triggered dosing reduces total medication and duration
• Citation: Amato L, et al. Cochrane Database Syst Rev. 2010;(3):CD005063. PMID: 20238337. DOI: 10.1002/14651858.CD005063.pub3

Brief Interventions for Alcohol Problems (Cochrane 2018)

• Effective for hazardous/harmful drinkers
• Reduces weekly alcohol consumption by 20-30g
• NNT approximately 8 for reduction to low-risk levels
• Citation: Kaner EF, et al. Cochrane Database Syst Rev. 2018;2:CD004148. PMID: 29476653. DOI: 10.1002/14651858.CD004148.pub4

Additional Key Evidence

AUDIT Validation Study (Saunders 1993)

• WHO-developed screening instrument
• 10-item questionnaire validated across multiple cultures
• Sensitivity 92%, Specificity 94% for hazardous drinking
• Citation: Saunders JB, et al. Addiction. 1993;88(6):791-804. PMID: 8329970. DOI: 10.1111/j.1360-0443.1993.tb02093.x

Wernicke's Encephalopathy Treatment (Thomson 2002)

• Royal College of Physicians guidance on ED management
• High-dose parenteral thiamine essential
• Oral thiamine inadequate for treatment or prophylaxis
• Citation: Thomson AD, et al. Alcohol Alcohol. 2002;37(6):513-521. PMID: 12414541. DOI: 10.1093/alcalc/37.6.513

DSM-5 Criteria Validation (Hasin 2013)

• Validated 11-item AUD criteria
• Severity continuum (mild/moderate/severe) demonstrated
• Good reliability and validity
• Citation: Hasin DS, et al. JAMA Psychiatry. 2013;70(12):1362-1371. PMID: 24154100. DOI: 10.1001/jamapsychiatry.2013.2512

Genetics of Alcohol Dependence (Edenberg 2013)

• Heritability approximately 50%
• Key genes: ADH1B, ALDH2, GABRA2, OPRM1, DRD2
• Gene-environment interactions important
• Citation: Edenberg HJ, Foroud T. Nat Rev Gastroenterol Hepatol. 2013;10(8):487-494. PMID: 23712313. DOI: 10.1038/nrgastro.2013.86

Global Burden of Alcohol (GBD 2016)

• Alcohol responsible for 2.8 million deaths globally per year
• 5.1% of global disease burden
• Leading risk factor in 15-49 age group
• Citation: GBD 2016 Alcohol Collaborators. Lancet. 2018;392(10152):1015-1035. PMID: 30146330. DOI: 10.1016/S0140-6736(18)31310-2

CAGE Questionnaire Validation (Ewing 1984)

• 4-item screening tool
• Sensitivity 84%, Specificity 95% at ≥2 cutoff for alcohol problems
• Citation: Ewing JA. JAMA. 1984;252(14):1905-1907. PMID: 6471323. DOI: 10.1001/jama.1984.03350140051025

Motivational Interviewing Meta-Analysis (Lundahl 2010)

• 119 studies included
• Consistent small-medium effect size (d=0.22-0.28)
• Effective across multiple health behaviours including alcohol
• Citation: Lundahl BW, et al. J Consult Clin Psychol. 2010;78(6):868-884. PMID: 21114344. DOI: 10.1037/a0021212

Disulfiram Supervised Administration (Jorgensen 2011)

• Meta-analysis of supervised vs unsupervised disulfiram
• Supervised disulfiram significantly more effective than unsupervised
• NNT 8-12 for supervised treatment
• Citation: Jorgensen CH, et al. Alcohol Clin Exp Res. 2011;35(10):1179-1187. PMID: 21535029. DOI: 10.1111/j.1530-0277.2011.01491.x

Evidence Summary Table

---

11. Patient/Layperson Explanation

What is Alcohol Dependence?

Alcohol dependence, now often called Alcohol Use Disorder (AUD), means your body and mind have become so used to alcohol that you feel you need it to function normally. It's a medical condition — not a sign of weakness or a character flaw — and it is highly treatable.

Key features include:

• Finding it hard to stop drinking even though you want to
• Needing to drink more to get the same effect (tolerance)
• Feeling unwell when you stop drinking (withdrawal symptoms)
• Drinking taking priority over other things in your life
• Continuing to drink despite knowing it's causing problems

Why Does It Happen?

Alcohol changes the chemistry in your brain. With regular heavy use, your brain adjusts to expect alcohol and needs it to feel "normal." This leads to:

• Strong cravings and urges to drink
• Physical symptoms when you stop (tremors, sweating, anxiety)
• Finding it very difficult to cut down or stop

Risk factors include:

• Family history (genes account for about half the risk)
• Starting drinking at a young age
• Mental health problems like depression or anxiety
• Traumatic experiences
• Being around heavy drinking

How Is It Treated?

1. Detox (Medically-Assisted Withdrawal) If you've been drinking heavily for a while, stopping suddenly can be dangerous. Doctors can prescribe medication (usually chlordiazepoxide or similar) to help you stop safely and prevent dangerous withdrawal symptoms. This usually takes 7-10 days.

2. Vitamin Treatment You'll be given thiamine (vitamin B1) — this is extremely important to protect your brain from alcohol-related damage. If there's any concern about brain effects, this is given as an injection or intravenous drip.

3. Support to Stay Sober

• Talking therapies: Counselling, CBT, or motivational interviewing help you understand your drinking and develop strategies to stay sober
• Support groups: Alcoholics Anonymous (AA), SMART Recovery, and other mutual aid groups provide peer support
• Family involvement: Involving family members can help

4. Medication to Prevent Relapse Several medications can help:

• Acamprosate: Reduces cravings and helps maintain abstinence
• Naltrexone: Makes drinking less rewarding
• Disulfiram (Antabuse): Makes you feel very unwell if you drink (deterrent effect)

What to Expect

• Withdrawal symptoms (tremor, anxiety, sweating) are worst in the first week but get much better
• Sleep may be disturbed for several weeks but will improve
• Mood often improves significantly within weeks of stopping
• Physical health begins to recover — liver damage can heal, energy improves
• Recovery is a journey — many people have setbacks, but each attempt builds towards success
• Lasting recovery is absolutely possible — many people go on to live full, healthy lives

When to Seek Urgent Help

Call 999 or go to A&E if you experience:

• Confusion or disorientation
• Seizures (fits)
• Seeing or hearing things that aren't there
• Very rapid heartbeat, shaking, or sweating severely
• Thoughts of suicide or self-harm
• Vomiting blood or passing dark, tarry stools

Where to Get Help

• Your GP: The first point of contact for most people
• Drinkline (UK): 0300 123 1110 (free, confidential advice)
• Alcoholics Anonymous UK: 0800 9177 650, www.alcoholics-anonymous.org.uk
• SMART Recovery UK: www.smartrecovery.org.uk
• Alcohol Change UK: www.alcoholchange.org.uk
• We Are With You: www.wearewithyou.org.uk
• Local drug and alcohol services: Ask your GP for referral

Key Messages

1. You're not alone — alcohol problems are extremely common
2. It's a medical condition — not a moral failing
3. Treatment works — many people recover fully
4. Don't stop suddenly if you've been drinking heavily — seek medical help first
5. Relapse is common and doesn't mean failure — each attempt helps
6. Recovery improves all areas of life — health, relationships, work, mood

---

12. Viva Voce Questions & Model Answers

Core Knowledge Questions

Q1: What are the DSM-5 criteria for Alcohol Use Disorder and how is severity graded?

Model Answer: AUD is diagnosed when 2 or more of 11 criteria are met within a 12-month period. The criteria span four domains: impaired control (drinking more/longer than intended, unsuccessful efforts to cut down, time spent obtaining/using/recovering, craving), social impairment (failure to fulfil role obligations, continued use despite interpersonal problems, giving up activities), risky use (use in hazardous situations, continued use despite physical/psychological problems), and pharmacological features (tolerance, withdrawal). Severity is graded as mild (2-3 criteria), moderate (4-5), or severe (6+).

Q2: Describe the pathophysiology of alcohol withdrawal and explain why it can be life-threatening.

Model Answer: Chronic alcohol exposure causes neuroadaptation: GABA-A receptors are downregulated while NMDA glutamate receptors are upregulated. When alcohol is abruptly removed, there is loss of GABA-mediated inhibition combined with unopposed glutamate-mediated excitation, producing CNS hyperexcitability. This manifests initially as tremor, tachycardia, hypertension, and anxiety. Severe cases progress to seizures (due to excitotoxicity) and delirium tremens (marked by confusion, hallucinations, severe autonomic instability, and fever). DTs carries 5-15% mortality if untreated due to hyperthermia, cardiovascular collapse, and complications.

Q3: A 55-year-old man with alcohol dependence presents with confusion and unsteady gait. What is your immediate management?

Model Answer: The priority is suspected Wernicke's encephalopathy — a medical emergency. Immediate management: (1) Pabrinex IV 2-3 pairs TDS — give thiamine BEFORE any glucose-containing fluids; (2) Check and correct blood glucose, electrolytes (Mg2+, K+, PO4-); (3) Assess for other causes of confusion (hypoglycaemia, head injury, sepsis, subdural haematoma, hepatic encephalopathy); (4) Full neurological examination looking for the classic triad (only present in 10-16%); (5) Maintain hydration; (6) Monitor closely for withdrawal; (7) Continue IV thiamine until no further improvement, minimum 5 days for suspected Wernicke's.

Clinical Application Questions

Q4: Compare and contrast acamprosate and naltrexone for relapse prevention.

Model Answer: Both are first-line options per NICE. Acamprosate modulates glutamate/GABA balance, normalising neurotransmission disrupted by chronic alcohol. It's started after complete detox, dosed 666mg TDS, and has best evidence for maintaining abstinence (NNT 9). Contraindicated in severe renal impairment. Naltrexone is an opioid antagonist that blocks alcohol's rewarding effects via endorphin system. Dosed 50mg OD orally or 380mg IM monthly, it primarily reduces heavy drinking days (NNT 12) rather than promoting complete abstinence. Contraindicated in opioid dependence (precipitates withdrawal) and hepatic failure. Choice depends on patient goals — acamprosate for abstinence-oriented, naltrexone if harm reduction acceptable or abstinence motivation uncertain.

Q5: How would you screen for and assess alcohol problems in primary care?

Model Answer: I would use a structured approach: (1) Routine screening with AUDIT or AUDIT-C (brief 3-question version) for all new registrations and opportunistically; (2) AUDIT score interpretation: 0-7 low risk, 8-15 hazardous (brief intervention), 16-19 harmful (extended intervention), 20+ possible dependence (specialist referral); (3) If dependence suspected, assess severity with SADQ; (4) Laboratory markers (GGT, MCV, LFTs, CDT) support assessment but shouldn't replace history; (5) Physical examination for stigmata of chronic liver disease and complications; (6) Mental health screen (depression, anxiety, suicidality common); (7) Social assessment (housing, employment, support); (8) Readiness to change assessment guides intervention selection.

Q6: Outline your management of a patient in moderate alcohol withdrawal (CIWA-Ar score 14).

Model Answer: For moderate withdrawal (CIWA-Ar 10-18) in a patient without risk factors for complicated withdrawal: (1) Consider community vs inpatient — if good social support, no prior seizures/DTs, no significant comorbidity, community appropriate; (2) Prescribe fixed reducing benzodiazepine regimen (e.g., chlordiazepoxide 20mg QDS tapering over 7-10 days) OR symptom-triggered dosing if adequate monitoring available; (3) Thiamine: Pabrinex IM 1 pair OD for 3-5 days if oral absorption uncertain, otherwise oral thiamine 100mg TDS; (4) Electrolyte supplementation; (5) Adequate hydration; (6) Daily assessment if community-based; (7) Clear advice on when to seek emergency help (seizures, confusion, hallucinations); (8) Plan for relapse prevention (medication discussion, referral to alcohol services, mutual aid).

Advanced/Viva Questions

Q7: Discuss the evidence for brief interventions in reducing alcohol consumption.

Model Answer: Brief interventions (5-15 minutes of structured advice) have strong evidence (Cochrane review, Level 1a) for reducing consumption in hazardous and harmful drinkers. They follow the FRAMES model: Feedback on risk, Responsibility for change with patient, Advice to reduce, Menu of options, Empathy, Self-efficacy support. Meta-analyses show they reduce weekly consumption by approximately 20-30g, with NNT of 8 for reduction to low-risk levels. They're cost-effective and deliverable in primary care, ED, and general hospital settings. Notably, they're less effective in established dependence — these patients need specialist treatment. Brief interventions represent the most evidence-based intervention for the largest group of problem drinkers (hazardous/harmful).

Q8: What are the key findings from the COMBINE study and their clinical implications?

Model Answer: COMBINE (2006, n=1,383) tested naltrexone, acamprosate, combined behavioural intervention (CBI), and medical management in a 2x2x2 design. Key findings: (1) Naltrexone with medical management was effective vs placebo; (2) Acamprosate did not separate from placebo — contrasting with European trials, possibly due to population differences (COMBINE recruited less severe dependence); (3) CBI did not provide additional benefit over medical management; (4) Medical management alone (regular medication visits with advice) was effective. Clinical implications: naltrexone is a validated first-line option; structured medical management is important; we shouldn't dismiss acamprosate based solely on COMBINE given positive European meta-analyses; psychosocial intervention intensity can be matched to patient need.

Q9: A patient with alcohol-related cirrhosis asks if it's too late to stop drinking. How would you counsel them?

Model Answer: I would provide honest but hopeful counselling: (1) It is absolutely NOT too late — stopping drinking is beneficial at any stage and is the single most important prognostic factor; (2) While cirrhosis itself cannot reverse, abstinence prevents progression to decompensation (ascites, variceal bleeding, hepatic encephalopathy); (3) 5-year survival in compensated cirrhosis with abstinence exceeds 80% vs under 50% with continued drinking; (4) Other organ systems (brain, heart, immune function) continue to improve; (5) Quality of life improves substantially; (6) I would acknowledge that stopping is difficult but emphasise excellent support is available; (7) Discuss treatment options, including medication (note: acamprosate may be preferred over naltrexone in liver disease; disulfiram contraindicated); (8) Link with specialist hepatology for monitoring and alcohol services for treatment.

---

13. References

Primary Clinical Guidelines

1. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence. NICE guideline [CG115]. 2011 (updated 2023). Available from: https://www.nice.org.uk/guidance/cg115
2. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications. NICE guideline [NG135]. 2017. Available from: https://www.nice.org.uk/guidance/ng135
3. World Health Organization. Global status report on alcohol and health 2018. Geneva: WHO; 2018. Available from: https://www.who.int/publications/i/item/9789241565639

Landmark Clinical Trials

4. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017. PMID: 16672078. DOI: 10.1001/jama.295.17.2003
5. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58(1):7-29. PMID: 8979210. DOI: 10.15288/jsa.1997.58.7
6. UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541. PMID: 16150764. DOI: 10.1136/bmj.331.7516.541

Cochrane Systematic Reviews

7. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332. PMID: 20824837. DOI: 10.1002/14651858.CD004332.pub2
8. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867. PMID: 21154349. DOI: 10.1002/14651858.CD001867.pub2
9. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;(3):CD005063. PMID: 20238337. DOI: 10.1002/14651858.CD005063.pub3
10. Kaner EF, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2:CD004148. PMID: 29476653. DOI: 10.1002/14651858.CD004148.pub4

Key Research Papers

11. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88(6):791-804. PMID: 8329970. DOI: 10.1111/j.1360-0443.1993.tb02093.x
12. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252(14):1905-1907. PMID: 6471323. DOI: 10.1001/jama.1984.03350140051025
13. Thomson AD, Cook CC, Touquet R, Henry JA; Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and emergency department. Alcohol Alcohol. 2002;37(6):513-521. PMID: 12414541. DOI: 10.1093/alcalc/37.6.513
14. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834-851. PMID: 23903334. DOI: 10.1176/appi.ajp.2013.12060782
15. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015-1035. PMID: 30146330. DOI: 10.1016/S0140-6736(18)31310-2
16. Edenberg HJ, Foroud T. Genetics and alcoholism. Nat Rev Gastroenterol Hepatol. 2013;10(8):487-494. PMID: 23712313. DOI: 10.1038/nrgastro.2013.86
17. Lundahl BW, Kunz C, Brownell C, Tollefson D, Burke BL. A meta-analysis of motivational interviewing: twenty-five years of empirical studies. Res Soc Work Pract. 2010;20(2):137-160. DOI: 10.1177/1049731509347850
18. Jorgensen CH, Pedersen B, Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res. 2011;35(10):1749-1758. PMID: 21535029. DOI: 10.1111/j.1530-0277.2011.01523.x
19. Day E, Bentham P, Callaghan R, Kuruvilla T, George S. Thiamine for Wernicke-Korsakoff Syndrome in people at risk from alcohol abuse. Cochrane Database Syst Rev. 2004;(1):CD004033. PMID: 14974055. DOI: 10.1002/14651858.CD004033.pub2
20. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830-842. PMID: 17606817. DOI: 10.1001/archpsyc.64.7.830

Patient Resources

• Drinkline (UK): 0300 123 1110
• Alcoholics Anonymous UK: 0800 9177 650, https://www.alcoholics-anonymous.org.uk
• SMART Recovery UK: https://www.smartrecovery.org.uk
• Alcohol Change UK: https://www.alcoholchange.org.uk
• We Are With You: https://www.wearewithyou.org.uk
• NHS Alcohol Support: https://www.nhs.uk/live-well/alcohol-advice/

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This content does not constitute medical advice for individual patients.